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Abstract.24
Background: Combining PET amyloid- (A) and tau imaging may be critical for tracking disease progression in
Alzheimer’s disease (AD).
25
26
Objective:We sought to characterize the relationship between A and tau ligands as well as with other measures of pathology.27
Methods: We conducted a multi-center observational study in early AD (MMSE > 20) participants aged 50 to 85 y. The
schedule included cognitive assessments (ADAS-Cog) and CSF measurement of A and tau at baseline and 6 months;
PET-CT imaging with A ([18F]AV45) and tau ([18F]AV1451) ligands at baseline.
28
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30
Results: 22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid
PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal
cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants
deteriorating faster despite lower levels of cortical tau. Cortical A associated with entorhinal cortex tau while CSF tau/A
ratio correlated strongly with cortical tau but not A.
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Conclusion: The negative relationship between age and cortical tau whereby younger patients with mild AD had relatively
greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology
while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau
performs better than PET-amyloid in predicting the best validated AD diagnostic marker—the CSF total tau/A ratio.
36
37
38
39
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INTRODUCTION36
The advent of positron emission tomography37
(PET) amyloid- (A) tracers [1] has made it possi-38
ble to detect A plaque load in vivo. The utility of A39
PET is that A burden predicts progression of mild40
cognitive impairment (MCI) to Alzheimer’s disease41
(AD) [2–4] and allows proof of amyloid pathology42
for the purposes of enrolling patients into AD clini-43
cal trials [5, 6]. However, A burden is a relatively44
poor correlate of disease progression in established45
AD: in vivo PET measures correlate poorly with46
symptom severity [7–10], and its spatial distribution47
differs from the pattern of cortical atrophy and glu-48
cose hypometabolism [7, 8, 11, 12].49
Until recently the only practical method of mea-50
suring tau pathology in vivo has been through CSF51
sampling [13, 14], which does not allow differenti-52
ation between aggregated tau pathology such as in53
AD and non-specific neurotoxicity. Recent advances54
however have led to the development of tau lig-55
ands for PET imaging [15, 16], which now enables56
localization of tau pathology in brain in life. One57
tracer, [18F]AV1451 (formerly called [18F]T807), has58
a binding pattern that follows closely NFTs in post-59
mortem studies [17, 18]. The binding of the tracer is60
highly specific to tau relative to A in vitro [17, 18]61
and has a differential uptake in AD patients relative62
to controls [19] and other tauopathies [20, 21]. Cru-63
cially, tau pathology measured with [18F]-AV145164
co-localizes with hypometabolism measured with65
FDG-PET [22] and is potentially useful for tracking66
disease progression and staging [23, 24].67
In this study, we sought to clarify, early in the68
symptomatic phase, the relationship between the69
tau-selective PET tracer [18F]AV1451 and the more70
established measures of AD pathology: A PET71
(using [18F]AV45 - florbetapir), CSF tau/p-tau, and72
A, as well as cognitive performance. We recruited73
patients with early AD (Mini-Mental State Exami-74
nation (MMSE) > 20) and obtained PET, CSF, and75
cognition measures at the study baseline. We repeated76
CSF and cognitive measures at 6 months. We hypoth-77
esized that in our early AD study group, PET A78
would correlate with tau signal in areas affected early 79
in the disease process and that change in cognitive 80
impairment over 6 months would be most demonstra- 81
ble in the subset of patients with greater A and/or 82
tau loading. In terms of PET/CSF relationship we 83
expected to replicate the reports of a negative corre- 84
lation between PET A cortical binding and CSF A 85
peptide [25, 26] and a positive relationship between 86
CSF and PET cortical tau measures [27, 28]. Our prin- 87
cipal aim of this analysis, though, was to determine 88
which PET measures would best predict the most 89
informative and currently available AD biomarker 90
(CSF tau/A ratio). 91
METHODS 92
Study design 93
A non-interventional multi-site study was carried 94
out at the 6 centers of excellence in the UK that consti- 95
tute the NIHR Translational Research Collaboration 96
in Dementia (NIHR Biomedical Research Centers or 97
Dementia Units associated with the following NHS 98
Trusts: Oxford University Hospitals (OUH), South 99
London and Maudsely (SLaM), Cambridge Univer- 100
sity Hospitals (CUHT), University College Hospital 101
London (UCLH), West London Mental Health Care 102
(WLMHC), and Newcastle Hospitals). Through local 103
memory clinic services, we recruited patients aged 104
50–85 with a diagnosis of probable AD (with no AD 105
pathophysiological evidence) according to National 106
Institute of Aging-Alzheimer’s Association (NIA- 107
AA) criteria [29]. Other inclusion criteria were i) 108
MMSE score of 20 and above, ii) Modified Rosen- 109
Hachinski Ischemic score of 4 or less, iii) being on 110
stable medication dose for any non-significant medi- 111
cal conditions for at least one month; iv) stable dose 112
for at least 3 months if treated with cholinesterase 113
inhibitors and/or memantine. 114
We aimed to enroll 24 patients across all sites. Par- 115
ticipants attended a screening visit where consent was 116
obtained and eligibility assessed. This was followed 117
by a baseline visit within 30 days, with three further 118
assessments assessment episodes over a six-month 119
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period (baseline, month 1, month 3 and month 6).120
Due to the demanding nature of the first and last vis-121
its, study procedures were completed over a period of122
up to 5 days. The original purpose of this study was123
to evaluate the acceptability and feasibility of such124
in-depth and high frequency biomarker sampling in125
view of organizing a larger study following a similar126
design.127
The full study schedule will be reported elsewhere128
but included demographic, clinical, and physical129
exam together with MMSE and assessment of sensory130
and motor impairment, mood and behavior, global131
function, and function. Cognition was assessed using132
pen and paper tests (Alzheimer’s Disease Assessment133
Scale – Cognitive subscale (ADAS-Cog) and MMSE)134
as well as computerized methods (Cambridge Neu-135
ropsychological Test Automated Battery (CANTAB)136
Paired Associates Learning (PAL), and Spatial Work-137
ing Memory (SWM)).138
At baseline, we performed PET for regional A139
and tau load with all imaging being performed at a140
single site in London (IMANOVA Ltd). One study141
site was too distant for participant travel and so was142
not included in the PET component of the trial (New-143
castle). The protocol included a T1-weighted MRI144
structural scan and two dynamic PET scans, one with145
[18F]AV45 (0–60 min, 150 ± 24 MBq) and one with146
[18F]AV1451 (0–120 min, 163 ± 10 MBq) to mea-147
sure A and tau respectively. The MRI scan was made148
on a Siemens 3T Tim Trio with a 32-channel phased149
array head coil. A 1 mm isotropic whole-brain struc-150
tural 3D T1-weighted MPRAGE was acquired using151
TI = 880 ms, TR = 2000 ms and FA = 8° with a par-152
allel imaging factor of 2 in 4 m: 54 s. For the PET153
scans, subjects were positioned in the PET scanner,154
after the insertion of a venous cannula in an antecu-155
bital or forearm vein, and a head-fixation device was156
used to minimize head movement during data acqui-157
sition. The PET scans were acquired on two Siemens158
PET/CT scanners (Hi-Rez Biograph 6 and Biograph159
6 TruePoint with TrueV, Siemens Healthcare, Erlan-160
gen, Germany) while for each subject, A and tau161
PET scans were acquired on the same scanner. A162
low-dose CT scan was performed immediately before163
each PET scan in order to estimate attenuation. A164
single intravenous bolus of [18F]AV45 (Florbetapir)165
tracer (150 ± 24MBq) for a 60 min A PET scan166
and [18F]AV1451 ([18F] T807) tracer (163 ± 10MBq)167
for a 120 min tau scan was injected to each subject.168
The dynamic images were reconstructed using a 2D169
Filtered Back Projection (FBP) algorithm resulting170
in a 128 × 128 matrix with 2 mm isotropic voxels.171
Corrections were applied for attenuation, randoms, 172
scatter, and tracer radioactive decay. All image pro- 173
cessing and analysis was performed in MIAKAT™ 174
(www.miakat.org). Dynamic PET data were cor- 175
rected for motion and a neuroanatomical atlas [30] 176
was nonlinearly registered to each subject using the 177
individuals T1 MRI scan to enable parcellation of 178
regions of interest. Regional standard uptake val- 179
ues (SUVr) with respect to cerebellar gray matter 180
were obtained for the 30–60 min time window for 181
[18F]AV45 and 60–120 min for [18F]AV1451 (one 182
participant stayed in the scanner for 110 min only – 183
we used 60–110 min time window in that instance) 184
to investigate static outcome measures. For both tau 185
and A measures regions of interest were identi- 186
fied on the basis of the Braak and Braak staging 187
model of AD [31] – entorhinal cortex (represented 188
by gyrus ambiens) and hippocampus (stages 1-2); 189
parahippocampus, fusiform gyrus, posterior cingu- 190
late, inferior temporal gyrus, thalamus, and amygdala 191
(stage 3-4); frontal, parietal as well superior tem- 192
poral and medial temporal cortices (stage 5-6). We 193
also extracted overall cortical SUVr values (cortex 194
defined as occipital, insular, temporal, frontal, cin- 195
gulate, and parietal cortices) for both A and tau 196
ligands. 197
Cerebrospinal fluid (CSF) was collected at 198
the baseline visit and 6-month follow-up. Total 199
tau (t-tau), phosphorylated tau (p-tau) and A 200
(i.e., A42) concentrations were measured using 201
INNOTEST enzyme-linked immunosorbent assays 202
(ELISAs) (Fujirebio Europe N.V., Gent, Belgium). 203
Well-established standard operating protocols for 204
sample collection and management were used [32] 205
and assays performed according to manufacturer’s 206
instructions, as previously described in detail [33]. 207
All measurements were performed by board-certified 208
laboratory technicians who were blinded to clini- 209
cal data. The measurements were performed on one 210
occasion using one batch of reagents. Intra-assay 211
coefficients of variation were below 10% and all 212
samples measured in the quantitative range of the 213
assays. 214
Statistical analysis 215
SPSS (Version 22) and the RStudio statistical pack- 216
age (Version 0.99.896) were used to analyze the 217
data. The relationship between A and tau in the 218
regions of interest and cortex were compared using 219
two-way Pearson’s correlations. We followed up any 220
significant relationships with linear models including 221
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age as a covariate to investigate its potential effects.222
The relationship between A/tau SUVr values and223
age was also explored using two-way Pearson’s224
correlations.225
In terms of cognitive measures analyses, we used226
repeated measures analyses of variance (ANOVAs)227
on memory-based tasks where longitudinal measure-228
ments were available (ADAS-Cog, PAL, SWM) to229
determine whether there was a significant change to230
cognition over the 6-month study period. Within sub-231
ject factor for each model was study visit (baseline,232
month 1, month 3, and month 6 for PAL and SWM;233
baseline and month 6 for ADAS-Cog) and outcome234
variables were respectively: ADAS-cog total score,235
PAL total projected errors and SWM between search236
errors. Sex was selected as between-subject factor for237
the three models while age was evaluated as a covari-238
ate. We explored the effect of PET tau and A SUVr239
levels on baseline and longitudinal cognition (cal-240
culated by subtracting baseline cognitive score from241
6-month score for cognitive variable) using linear242
models. We repeated these analyses with entorhinal243
cortex tau (due to a significant correlation we found244
between cortical A and entorhinal tau, see results245
section) and posterior cingulate A (due to reports of246
posterior cingulate A predicting cognitive progres-247
sion [3]) as independent variables. Only ADAS-Cog248
scores were included in these analyses as SWM and249
PAL mean error variables were not normally dis-250
tributed in the sample of patients who underwent251
PET.252
We analyzed CSF concentrations for A, tau, p-253
tau, and also generated tau/A ratios. We performed254
two-way Pearson’s correlations between selected255
SUVr values (cortical tau and A) and the four CSF256
measures at baseline visit (A, tau, p-tau, and tau/A257
ratio). To test the hypothesis that either cortical A or258
tau may predict CSF change over the 6-month study259
period we ran linear models with cortical A and260
tau as independent variables and CSF measures (tau,261
p-tau, A, and tau/A) as repeated dependent vari-262
ables (baseline and 6-month follow-up). Finally, we263
explored the CSF markers’ association with longi-264
tudinal cognition by performing linear models with265
baseline (i.e., visit 1) CSF tau, p-tau, A, and tau/A266
ratio as independent variables and ADAS-Cog and267
PAL score change over 6 months (i.e., baseline scores268
subtracted from 6-month scores) as dependent vari-269
ables (SWM scores were not included as they were270
not normally distributed in the subsample of patients271
who had baseline CSF). We tested the moderating272
effect of age in these models.273
Ethics 274
The study was approved by a National Research 275
Ethics Committee London on the 19th of Sept. 2014 276
– IRAS reference 14/LO/1467, IRAS project ID: 277
156309. All participants had mental capacity for 278
informed consent. 279
RESULTS 280
Recruitment 281
Eight participants were excluded at screening: 5 282
because they failed to meet study entry criteria, one 283
because of having had a recent PET scan, one for 284
withdrawal of consent, and one for an unspecified 285
reason. Twenty-two participants were included after 286
screening and 20 remained at follow-up (one drop- 287
out due to consent withdrawal and one exclusion 288
due to psychosis). All 20 participants completed 289
the cognitive assessments as planned (CANTAB and 290
paper-based tests). Out of the 20 participants, 16 had 291
CSF testing at baseline (2 did not complete due to 292
medical reasons and 2 due to logistical reasons). At 293
follow-up CSF was taken from 16 participants – rea- 294
sons for not doing the testing were again medical (2) 295
and logistical (2) but this was the case for three peo- 296
ple who had completed the baseline CSF (i.e., three 297
participants who had follow-up CSF did not have 298
baseline CSF). Therefore 13 participants had CSF 299
testing both at baseline and follow-up. We planned 300
to perform PET imaging at five out of the six study 301
centers and 15 of the 16 eligible study completers 302
underwent imaging (one missing imaging because of 303
logistical reasons). PET A data with [18F]AV45 was 304
successfully obtained for 14 out of 15 participants 305
(1 participant had unusable data due to excessive 306
motion) and PET tau data with [18F]AV1451 for 12 307
of the 15 participants (3 participants did not complete 308
at least 70 min of image acquisition). 309
See Table 1 for demographics of patients included 310
in the study. 311
PET tracer analyses 312
Our regional correlation analysis (12 participants 313
included) revealed that cortical A was associated 314
with tau in the entorhinal cortex (r = 0.6, p = 0.04, 315
Fig. 2A), thalamus (r = 0.72, p < 0.01) and parahip- 316
pocampus (r = 0.63, p = 0.03). This relationship was 317
not moderated by age; see Fig. 1 for a topographical 318
representation of tau and A binding in individual 319
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Table 1
Demographics
Demographics Mean SD
Sex 11M 9F
Age 71.3 8.4
Education (y) 14.7 3.9
Premorbid IQ 116.0 8.2
MMSE 24.8 2.4
ADAS-COG 14.6 6.1
Rosen-Hachinski score 0.7 0.9
Clinical Dementia Rating score 0.63 0.27
Geriatric Depression Scale 2.2 1.34
Bristol Activities of Daily Living Scale 3.2 3.0
participants. Age correlated negatively with cortical320
(r = –0.83, p < 0.01, or= –0.02, p < 0.001) as well as321
regional tau load across Braak stage regions: entorhi-322
nal cortex non-significant at trend (r = –0.56, p = 0.06,323
Fig. 2B), hippocampus (r = –0.62, p = 0.03), occipital324
(r = –0.77, p < 0.01) parietal (r = –0.90, p < 0.001) and325
frontal cortices (r = –0.60, p = 0.04). There was no326
statistically significant relationship between cortical327
A SUVr values and age.328
Cognitive test results 329
Twenty participants completed serial pen and 330
paper (ADAS-Cog at baseline and month 6) and 331
computerized cognitive measures (PAL and SWM 332
CANTAB tests at baseline, month 1, month 3 and 333
month 6). Unsurprisingly, in this mildly demented 334
group, no model showed significant change in 335
cognition. 336
We proceeded to explore the relationship between 337
ADAS-Cog scores (baseline cross-sectional and over 338
time) and cortical tau, entorhinal tau, and cortical A 339
posterior cingulate SUVr values for the 12 partici- 340
pants who underwent both tau and amyloid PET that 341
was done at baseline. In terms of the baseline cross- 342
sectional ADAS-Cog models, there were no main 343
effects of any of the four PET variables, and these 344
models were not modulated by age. In the longitu- 345
dinal ADAS-Cog models (i.e., baseline ADAS-Cog 346
scores subtracted from 6-month scores) entorhinal 347
tau loading did not exert a main effect (= –1.4, CI 348
[–19.4, 16.6], p = 0.9), but its interaction with age 349
Fig. 1. Topographical plots of PET SUVr levels for the 12 participants who underwent both A and tau imaging. A and B demonstrate,
respectively, [18F]AV45 (A) and [18F]AV1451 (tau) topographical distribution of SUVr signal across the 12 participants (each column
represents a participant; participants have been ordered according to baseline MMSE scores).
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Fig. 2. PET tau and A scatterplots: A) Cortical A (vertical axis) and entorhinal tau (horizontal axis) scatterplot. B) Age (vertical axis)
and entorhinal (horizontal axis) tau scatterplot. C) Illustration of the interaction between age and entorhinal tau on cognitive progression.
ADAS-Cog score change from baseline to 6-month follow-up on the vertical axis, entorhinal tau on the horizontal axis. Scatterplot is split
with left side featuring those under the median age (72.5 y) and the right with those above it. D) ADAS-Cog score change from baseline to
6-month follow-up (vertical axis) and cortical A (horizontal axis).
was statistically significant (= 0.3, CI [–0.04, 0.61],350
p = 0.03). This was due to older patients being dis-351
proportionately affected by tau loading (see Fig. 2C).352
Cortical tau did not exert a main effect in the ADAS-353
Cog longitudinal model, and this was not modulated354
by age. Both cortical and posterior cingulate A355
SUVr levels did not reach significance in respect to356
the cognitive progression model (Fig. 2D). Age and357
period since symptom onset did not interact signifi-358
cantly with PET A values in these models.359
CSF analyses360
CSF was collected from 16 patients at baseline and361
from 16 patients at follow-up (13 patients had both362
baseline and follow-up CSF collection). We found363
that cortical tau correlated strongly with baseline CSF364
tau (r = 0.80, p < 0.01), p-tau (r = 0.70, p = 0.02) as365
well as tau/A ratio (r = 0.73, p = 0.02; Fig. 3) but366
not A. Cortical A did not correlate with baseline367
CSF measures (tau, p-tau, A, or tau/A).368
In the linear models exploring whether cortical A 369
or tau predict CSF change over the 6-month study 370
period, we found that neither cortical tau nor Awere 371
statistically significant in predicting change in tau, 372
p-tau, A, or tau/A over the 6-month period. 373
To test the hypothesis that CSF markers at baseline 374
predict cognitive decline, we analyzed the relation- 375
ship between four CSF variables (baseline CSF tau, 376
p-tau, A, and tau/A ratio) to longitudinal cognitive 377
change (ADAS-Cog and PAL tests). Baseline CSF 378
tau, p-tau, and A exerted significant main effects in 379
the ADAS-Cog longitudinal model: tau (= 0.0095, 380
CI [2.33 0.018]p < 0.05), p-tau (= 0.0974, CI [0.002 381
0.192] p < 0.05), and A (= 0.0492, CI [0.004 382
0.081] p = 0.03). Tau but not A interacted with age in 383
these models (= 0.004, CI [4.199 0.001] p < 0.05); 384
the interaction in the p-tau model did not reach signif- 385
icance. There was no main effect of baseline tau/A 386
ratio on the ADAS-Cog longitudinal model. There 387
were no main effects of baseline tau, p-tau, A, or 388
tau/A ratio in the PAL longitudinal models. 389
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Fig. 3. CSF tau/A relationship with PET cortical tau (A) and A (B). On the vertical axes are CSF tau/A ratios and on the horizontal axes
are cortical tau (A) and cortical A (B). Visit 1 and Visit 2 CSF measurements in dark gray rombes and light gray rectangles respectively.
PET scanning was done at baseline only.
DISCUSSION390
In this study of people diagnosed with mild AD, we391
explored the relationships between the recently devel-392
oped PET tau tracer, [18F]AV1451, and established393
AD research measures: PET A ([18F]AV45), CSF394
measures of tau and A and cognitive measures. We395
found a relationship between tau and age, whereby396
younger patients with mild AD had relatively greater397
tau burden in the entorhinal cortex. Entorhinal cortex398
was also the only region where PET measures of tau399
associated with cortical A binding. The relationship400
between tau and age was underscored by the finding401
that cognitive deterioration over the 6-month period402
was associated with tau levels in the entorhinal cor-403
tex especially in older participants. Finally, cortical404
tau correlated strongly with CSF tau measures but405
there was no relationship between A PET and CSF406
measures.407
Age effects408
The finding of a negative relationship between age409
and tau deposition appears at odds with evidence for410
rising MTL tau levels with age [23] but may be reflec-411
tive of different rates of tau accumulation depending412
on age of illness onset. A recent tau PET study pro-413
vided evidence in support of this by showing that414
while in unimpaired people tau deposition in MTL415
correlates with age, tau propagation in MCI extends416
beyond MTL (i.e., inferotemporal and fusiform gyri)417
in younger and more cognitively impaired individuals418
[34]. This is consistent with studies showing that in419
late-onset AD the medial temporal lobes are prefer-420
entially affected while younger onset disease features421
greater cortical degeneration and relative sparing of422
the hippocampus [8, 35–38].423
The age effects observed here may reflect the view 424
that that AD features distinct clinico-pathological 425
phenotypes: a typical, late-onset form affecting pref- 426
erentially the medial temporal lobe and atypical, 427
younger-onset forms that affect the whole cortex [39]. 428
These younger-onset forms are less dependent on 429
APOE4 risk factors, progress quicker and have a more 430
varied clinical presentation [40, 41]. This form of 431
AD may be a primarily tau-driven disease as in the 432
current study as well as in others there was no rela- 433
tionship between A and age [8]. The relationship 434
we see between age and tau pathology suggests a 435
continuum of disease between young-onset and late- 436
onset disease with the younger group in the present 437
study with an onset in their mid-60 s sharing some of 438
characteristics of young-onset dementia, more usu- 439
ally considered a disorder with an onset before the 440
age of 60. 441
Effects of tau and Aβ on change in cognition 442
Overall, there was no significant deterioration of 443
cognition in our group over the 6-month period, 444
as expected in this very mild group where longer 445
periods are required to observe disease progression. 446
Nonetheless, we found both PET and CSF measures 447
of tau but not amyloid pathology were associated 448
with worsening cognition at 6 months. In the PET 449
models, this association between tau and cognition 450
appeared to be driven primarily by older participants 451
as entorhinal tau levels in the group older than the 452
mean 72.5 y were positively related to cognitive pro- 453
gression, while there was no such relationship in 454
the younger group. The interacting effect of age and 455
tau accumulation on cognitive progression was repli- 456
cated in the CSF tau models. That tau correlates better 457
with clinical features of dementia than A pathology 458
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is in line with other early studies using PET imaging459
of tau pathology, showing that Braak staging (esti-460
mated automatically on the basis of spatial pattern461
of tau accumulation) correlates with extent of base-462
line [23, 24] and longitudinal [23] cognitive deficits.463
We interpret our finding of interaction between tau464
measures and age on cognition as a suggestion that465
tau accumulation in the MTL structures such as the466
entorhinal cortex has a disproportionately negative467
effect on cognition in older age, i.e., in older people468
relatively lower levels of tau in the entorhinal cor-469
tex are associated with cognitive deterioration. These470
effects may be due to the lower cognitive reserve in471
older people or to other pathology contributing to472
dementia in this age group.473
Relationship between CSF and PET biomarkers474
Finally, we compared tau and A PET signal with475
the best validated marker of AD pathology—tau/A476
CSF ratio [42]. We found that it was baseline cortical477
tau but not A that associated with the tau/A ratio.478
This relationship was due to a correlation between479
cortical and CSF measures of tau which is in line480
with the two published studies comparing CSF and481
PET tau [27, 43]. These results suggest that tau is482
more closely aligned with pathological processes at483
the stage of developed illness. This could be due484
to amyloid reaching a plateau around the time of485
symptom onset as has been suggested previously486
[44].487
An important difference from existing literature488
was the lack of a significant negative relationship489
between cortical A as measured with PET and CSF490
A [25, 45]. Most studies examining this relationship491
included both amyloid-positive and amyloid-negative492
individuals; within either group the correlations are493
weaker or absent [46]. Our group was relatively494
homogeneous in terms of PET amyloid signal and495
therefore the most likely explanation for the negative496
result was the modest sample size of our cohort and497
so should be treated with caution.498
We also explored the relationship between PET499
cortical A signal and tau ligand binding in the dif-500
ferent regions used for Braak staging. We found that501
only entorhinal tau correlated with cortical amyloid.502
This finding could be interpreted as supportive for503
the ‘trigger and bullet’ hypothesis of the interac-504
tion between A and tau in AD pathophysiology505
[47]—that a critical level of A burden needs to be506
reached before that toxic tau cascade is triggered507
starting from the entorhinal cortex. However, the508
existing evidence suggests that tau accumulation in 509
the MTL is part of normal aging with tau propagat- 510
ing beyond MTL only in those who are classed as A 511
positive [23]. 512
Strengths and limitations 513
This is a study with notable strengths and weak- 514
nesses. In terms of strengths, it is one of the few 515
studies to report not only both A and tau imaging 516
but also CSF markers of A and tau pathology, and 517
with all measures being conducted within a very short 518
time period. A further strength is the longitudinal (6 519
month) data on cognition and CSF AD biomarkers. 520
Last but not least, it demonstrated the feasibility of a 521
multicenter, in-depth and high frequency biomarker 522
sampling design which may be crucial for identify- 523
ing temporal trends in AD biomarker evolution and 524
clinical trials design. In terms of limitations, firstly 525
the study was designed to assess the feasibility and 526
acceptability of the in-depth and frequent biomarker 527
investigations and therefore was not powered for mild 528
to moderate effects sizes. As a result, most of the 529
results should be treated with caution – for instance 530
the lack of replication of a negative relationship 531
between CSF A and tau may be a Type II error on 532
account of the small sample size. Secondly, the study 533
likely suffers from a recruitment bias; the sample con- 534
sisted of 2–4 patients per site who for the purposes 535
of quick study completion were highly motivated and 536
known to the study investigators and so may not be 537
representative of a randomly selected mild AD group. 538
Thirdly, the study included a modest in length follow- 539
up (6 months), which is likely to be insufficient to 540
answer questions about the longitudinal relationship 541
of AD biomarkers in the mild stages of the disease. 542
Lastly, this study did not include a control group 543
which precluded the possibility for assessing pro- 544
gression data against normative data. We are now 545
in the process of attempting to address the multi- 546
tude of limitations by setting up a large, multi-site 547
study informed by the acceptability and feasibility 548
currently reported study. In terms of PET methodol- 549
ogy, tau tracers are still early in their development 550
and further developments are needed to clarify their 551
reliability and specificity. We note that [18F]AV-1451 552
used in this study has off-target binding of relevance 553
on some neurodegenerative disorders [17], although 554
neuromelanin has been ruled out as a significant 555
determinant of binding in AD [21], and the cortical 556
distribution is unlikely to be explained by monoamine 557
oxidase. 558
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Conclusion559
In this study, we found a significant relationship560
between age and cortical PET tau whereby younger561
patients with similar severity of clinical disease have562
disproportionally more tau pathology. These results563
argue that younger age onset AD may be primarily564
driven by tau pathology while AD developing later565
in life may be driven by a multitude of pathologi-566
cal mechanisms. Nonetheless, cortical A correlated567
with tau in the entorhinal cortex, the origin of AD568
pathology which suggests that irrespective of age,569
AD is a disorder triggered by A deposition and570
progressed through tau pathology. Critically, in the571
stage of developed illness cortical tau is a better cor-572
relate than A of the best validated AD diagnostic573
marker—the CSF tau/A ratio. The results of this574
study remain to be replicated in larger samples.575
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